Drug Safety Advisories : A need for international coordination

UBC Faculty Research and Publications

Drug Safety Advisories : A need for international coordination Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 128 highlights the need for international coordination on drug safety advisories. Conclusions: Observational studies have identified signals of serious harms from long-term PPI exposure, including an increased risk of death. Even large RCTs may not detect these, if exposure or follow-up are insufficiently long. The COMPASS trial findings are not inconsistent with contemporaneous findings from observational studies. Clinicians and patienConclusions Better awareness of drug safety advisories from their own and other countries could help prescribers and patients seek the safest available drugs. When drug safety warnings differ, clinicians and the public need to know why. Regulators should provide the underlying rationale and an international context when issuing new drug safety warnings.ts can reverse the relentless expansion of long-term PPI exposure by reviewing indications and considering potential harms as well as benefits.

Item Metadata

Title	Drug Safety Advisories : A need for international coordination
Alternate Title	Therapeutics Letter 128
Creator	Therapeutics Initiative (University of British Columbia)
Date Issued	2020-12
Description	Therapeutics Letter 128 highlights the need for international coordination on drug safety advisories. Conclusions: Observational studies have identified signals of serious harms from long-term PPI exposure, including an increased risk of death. Even large RCTs may not detect these, if exposure or follow-up are insufficiently long. The COMPASS trial findings are not inconsistent with contemporaneous findings from observational studies. Clinicians and patienConclusions Better awareness of drug safety advisories from their own and other countries could help prescribers and patients seek the safest available drugs. When drug safety warnings differ, clinicians and the public need to know why. Regulators should provide the underlying rationale and an international context when issuing new drug safety warnings.ts can reverse the relentless expansion of long-term PPI exposure by reviewing indications and considering potential harms as well as benefits.
Subject	Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Iatrogenic Disease; Patient Safety
Genre	Other
Type	Text
Language	eng
Notes	The UBC TI is funded by the BC Ministry of Health to provide evidence-based information about drug therapy. We neither formulate nor adjudicate provincial drug policies.
Date Available	2023-06-20
Provider	Vancouver : University of British Columbia Library
Rights	Attribution-NonCommercial-NoDerivatives 4.0 International
DOI	10.14288/1.0433707
URI	http://hdl.handle.net/2429/85117
Affiliation	Medicine, Faculty of; Anesthesiology, Pharmacology and Therapeutics, Department of
Peer Review Status	Reviewed
Scholarly Level	Faculty; Researcher
Rights URI	http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository	DSpace

Open Collections

UBC Faculty Research and Publications